Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
H Döhner, E Estey, D Grimwade… - Blood, The Journal …, 2017 - ashpublications.org
The first edition of the European LeukemiaNet (ELN) recommendations for diagnosis and
management of acute myeloid leukemia (AML) in adults, published in 2010, has found …
management of acute myeloid leukemia (AML) in adults, published in 2010, has found …
Current approaches in the treatment of relapsed and refractory acute myeloid leukemia
NR Ramos, CC Mo, JE Karp, CS Hourigan - Journal of clinical medicine, 2015 - mdpi.com
The limited sensitivity of the historical treatment response criteria for acute myeloid leukemia
(AML) has resulted in a different paradigm for treatment compared with most other cancers …
(AML) has resulted in a different paradigm for treatment compared with most other cancers …
Tracing the origins of relapse in acute myeloid leukaemia to stem cells
In acute myeloid leukaemia, long-term survival is poor as most patients relapse despite
achieving remission. Historically, the failure of therapy has been thought to be due to …
achieving remission. Historically, the failure of therapy has been thought to be due to …
FDA approval summary: mylotarg for treatment of patients with relapsed or refractory CD33‐positive acute myeloid leukemia
KJ Norsworthy, CW Ko, JE Lee, J Liu, CS John… - The …, 2018 - academic.oup.com
Abstract On September 2, 2017, the US Food and Drug Administration approved
gemtuzumab ozogamicin (GO; Mylotarg; Pfizer, New York City, NY) for treatment of relapsed …
gemtuzumab ozogamicin (GO; Mylotarg; Pfizer, New York City, NY) for treatment of relapsed …
Venetoclax and idasanutlin in relapsed/refractory AML: a nonrandomized, open-label phase 1b trial
This phase 1b trial (NCT02670044) evaluated venetoclax-idasanutlin in patients with
relapsed/refractory (R/R) acute myeloid leukemia (AML) ineligible for cytotoxic …
relapsed/refractory (R/R) acute myeloid leukemia (AML) ineligible for cytotoxic …
Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort
Although hypomethylating agents (HMAs) are frequently used in the frontline treatment of
older acute myeloid leukemia (AML) patients, little is known about their effectiveness in …
older acute myeloid leukemia (AML) patients, little is known about their effectiveness in …
[HTML][HTML] Hematopoietic stem cell fate through metabolic control
K Ito, K Ito - Experimental hematology, 2018 - Elsevier
Highlights•Specific modes of metabolism play important roles in hematopoietic stem cell
(HSC) self-renewal.•Heterogeneity and technical challenges have prevented the elucidation …
(HSC) self-renewal.•Heterogeneity and technical challenges have prevented the elucidation …
Metabolism as master of hematopoietic stem cell fate
HSCs have a fate choice when they divide; they can self-renew, producing new HSCs, or
produce daughter cells that will mature to become committed cells. Technical challenges …
produce daughter cells that will mature to become committed cells. Technical challenges …
Clinical development of IDH1 inhibitors for cancer therapy
M Zarei, JJ Hue, O Hajihassani, HJ Graor… - Cancer Treatment …, 2022 - Elsevier
Abstract Isocitrate dehydrogenase 1 (IDH1) has been investigated as a promising
therapeutic target in select cancers with a mutated version of the enzyme (mtIDH1). With …
therapeutic target in select cancers with a mutated version of the enzyme (mtIDH1). With …
Treatment of relapsed/refractory acute myeloid leukaemia in adults
A Rashidi, DJ Weisdorf… - British journal of …, 2018 - Wiley Online Library
The prognosis of relapsed acute myeloid leukaemia (AML) is poor and treatment is
challenging. While the most potent treatment modality for patients who achieve a complete …
challenging. While the most potent treatment modality for patients who achieve a complete …